|Articles|December 8, 2021

Rho Acquires Dokumeds

Rho has announced that they have acquired Dokumeds, a privately-held European CRO. Established in 1995 and headquartered in Riga, Latvia, Dokumeds has 10 offices and is active across multiple continents. Terms were not disclosed.

The combined companies will continue to provide full service clinical development services, from investigational new drug applications to regulatory submissions.

Edgemont Partners served as the exclusive financial advisor to Rho on the transaction.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Rho Acquires Dokumeds

Related Content

What the "Dead Time" Problem Actually Is and Why It Matters for Real-Time Monitoring

ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment

What Inspection Readiness Actually Looks Like When It's Built In From the Start

The AI Churn Trap in Life Sciences and How to Break It

ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition

Trending on Applied Clinical Trials Online

The AI Churn Trap in Life Sciences and How to Break It

ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition

ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism

Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework

Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research